New reagent, in vivo-jetRNA® to tailor to pharmaceutical and research industry demand for mRNA technologies

Strasbourg, France, October 29, 2019 – Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of in vivo-jetRNA®, an innovative injectable mRNA transfection reagent. in vivo-jetRNA can be used for vaccination experiments, anti-cancer research, and in vivo functional studies in animals.

Polyplus-transfection has made in vivo transfection reagents available to the market since it launched its first transfection reagent, in vivo-jetPEI®, in 2001. This will be the seventh in vivo reagent and the 25th reagent in the product portfolio. As a result, Polyplus has the widest in vivo transfection reagent portfolio worldwide. Polyplus-transfection currently supplies in vivo-jetPEI transfection reagents to eight separate clinical trials. As a result of this experience, companies using in vivo-jetRNA would be able to benefit from the eighteen years of acquired knowledge and expertise by Polyplus-transfection regarding the application of these reagents. The in vivo-jetRNA injectable mRNA transfection reagent has been presented at the European Society of Cell and Gene Therapy 27th Annual Congress in Barcelona, Spain, 22-25 October, 2019.

Polyplus-transfection has launched in vivo-jetRNA as an alternative to viral methods for both vaccination and cancer research areas. in vivo-jetRNA is a ready-to-use solution that does not require the substantially long-term development currently required by market offerings to date. It is directly complexed with nucleic acid and injected into animals. Additionally, its adaptability enables multiple administration routes to target an organ of choice in all types of animals; especially the spleen and the lymphatic nodes that play a major role in vaccination.

Improvements in messenger RNA (mRNA) technologies, specifically over the last decade, have resulted in an increase in demand from pharmaceutical and research organizations for injectable mRNA transfection reagents. Polyplus-transfection has identified a demand for efficient and easy-to-use transfection solutions to administrate mRNA, usable up to clinical grade.

“The vaccination and oncology research markets continue to evolve and grow, and this increases and changes demand on an ongoing basis. As a result, Polyplus-transfection continues to develop and launch new reagent products for the changing demands of these markets,” said Karsten Wilking, CEO, Polyplus-transfection. “The current most used methods in the market have a development period that is too long to keep pace with innovation and market demand. This is causing substantial development bottlenecks. The new Polyplus-transfection in vivo mRNA transfection reagent will help alleviate these and will increase development in vaccination experiments and anti-cancer research.”

In vaccination, the application can be both preventative and curative. Researchers need a specific immune response against a specific antigen that is sufficient to trigger the targeted action. As plasmid DNA, mRNA can be used to transiently express a specific antigen into an organism or tissue. This antigen will be recognized by the immune system through antigen presenting cells and triggers a specific immune response. As a result, mRNA is specifically useful for this application because it can be used as self-adjuvant to boost an immune response. Finally, for cancer research, mRNA can be used to express a suicide gene to kill cancer cells.

More details of the product can be found here:

About Polyplus-transfection® SA

Polyplus-transfection® SA is a biotechnology company specializing in nucleic acid delivery solutions located close to the University of Strasbourg in Eastern France and a market leader for transfection reagents for cell & gene therapy.  Polyplus-transfection’s vast portfolio of delivery solutions can be used for all types of applications, from research and process development, all the way to clinical trials..

For more information, please visit the Polyplus-transfection web site at: